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SH3 domainThe Src-homology 3 (SH3) domain is one of the most frequent protein recognition modules (PRMs), being
represented in signal transduction pathways and in several pathologies such as cancer and AIDS. Grb2
(growth factor receptor-bound protein 2) is an adaptor protein that contains two SH3 domains and is
involved in receptor tyrosine kinase (RTK) signal transduction pathways. The HIV-1 transactivator factor Tat
is required for viral replication and it has been shown to bind directly or indirectly to several host proteins,
deregulating their functions. In this study, we show interaction between the cellular factor Grb2 and the HIV-1
trans-activating protein Tat. The binding is mediated by the proline-rich sequence of Tat and the SH3 domain
of Grb2. As the adaptor protein Grb2 participates in a wide variety of signaling pathways, we characterized at
least one of the possible downstream effects of the Tat/Grb2 interaction on the well-known IGF-1R/Raf/MAPK
cascade. We show that the binding of Tat to Grb2 impairs activation of the Raf/MAPK pathway, while
potentiating the PKA/Raf inhibitory pathway. The Tat/Grb2 interaction affects also viral function by inhibiting
the Tat-mediated transactivation of HIV-1 LTR and viral replication in infected primary microglia.ter, Medical School, Stanley S.
0112, USA. Tel.: +1 504 568
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Protein–protein interaction mediated by a conserved sequence
motif in one protein and a protein recognition module (PRM) in
another is a common mechanism of assembling protein complexes
participating in signal transduction pathways. Src homology 3 (SH3)
modules are conserved elements of about 60 amino acids present in a
large number of proteins which participate in a variety of biological
processes [1,2]. Although SH3 domains generally recognize a PxxP
motif in their binding partners, individual SH3 domains might possess
distinct speciﬁcities for putative ligands. At least part of this speciﬁcity
is thought to be determined by the amino acids ﬂanking the core
sequence [3,4], making the overall three-dimensional structure of the
PxxP-bearing protein speciﬁc only for certain SH3-carrying partners.
While protein–protein interactions mediated by SH3 domains
participate in many cellular processes, one of the best characterized
signaling pathways is the tyrosine kinase receptor mediated Ras
activation. Growth factor receptor-binding protein-2 (Grb2), consist-
ing of three domains, two SH3 and a single SH2 domain, is one of the
central factors in the Ras signaling cascade. Grb2 can recruit Ras
guanine nucleotide exchange factor, Sos, to the activated tyrosinekinase receptor at the plasma membrane, where Sos activates Ras [5].
Activated Ras then leads to activation of MAPK signaling cascade [6].
Besides its critical role in normal development [7], Grb2-mediated
mitogenic signals have been implicated in several human tumors
(reviewed in [8]).
The transactivating factor Tat is an 86–101 amino acid polypeptide
encoded by the HIV-1 virus [9]. Several studies have demonstrated the
importance of HIV-1 Tat in the viral replication cycle and in the
pathogenesis of AIDS [10,11]. Tat displays several important biological
activities affecting uninfected and infected cells by a paracrine/
autocrine mechanism due to secretion of Tat from infected cells and
its uptake by uninfected neighboring cells [12–14]. Tat has been
shown to modulate expression and activity of several cellular factors
deregulating a variety of signal transduction pathways [15]. For
instance the modulation of signaling pathways such as the MAPK or
the PI3-K pathways by Tat is well documented [16–26]. Given the
ability of Tat to directly interact with host factors, we sought to
examine the amino acid sequence of this viral protein for the presence
of protein–protein recognition elements. Similar to another HIV
protein, Nef [27], Tat also contains proline-rich motives which are
putative SH3-binding domains, one at the N-terminal and the other at
the C-terminus of the protein. In an SH3 domain binding screening,
we found that Grb2-derived peptides gave the highest probability
score of binding to Tat. GST-pull-down assay further revealed a
preferred binding of Tat to the C-terminal SH3 domain of Grb2. The
outcome of Tat/Grb2 interaction was evaluated in terms of cellular
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resulted in the attenuation of the MAPK pathway while potentiating
the Raf inhibitory pathway. Of interest, in terms of viral functions, we
found that Tat/Grb2 interaction decreased the activity of Tat on the
HIV-1 LTR, as determined by reduced levels of p24 in the medium of
HIV-1 infected human microglia.
Altogether our results provide evidence for a direct interaction of
Tat with Grb2, and possibly other SH3-bearing proteins, suggesting a
broad-spectrum mechanism for Tat-mediated deregulation of signal-
ing pathways.
2. Materials and methods
2.1. Cell culture, transfection, infection, recombinant proteins and
inhibitors
The human Glioblastoma cell line LN229 was maintained in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (GIBCO Invitrogen Co., Carlsbad, CA). Primary
human fetal microglia cells were isolated and cultured as previously
described [28]. Preparation of HIV-1, strain JRFL, stock and infection of
primary microglia were performed at a multiplicity of infection (MOI)
of 0.1, as described previously [28].
For transient expression experiments, LN229 cells were seeded on
60 mm dishes (BD Falcon™, Oakville, Ontario, Canada) at a density of
5×105 cells/plate, and the transfection was performed using FuGENE
6 Transfection reagent (Roche Diagnostics Corp., Indianapolis, IN)
according to the manufacturer's instructions. When required, 24 h
after transfection cells were washed with PBS twice and starved for
24 h in DMEMwithout FBS. Stimulationwas done by IGF-1 (40 ng/ml;
Invitrogen, Carlsbad, CA) for 0, 2 and 10 min and was stopped by
medium removal and placing on ice.
Recombinant Tat101 was from Immunodiagnostics (Woburn,
MA). Inhibitors, LY 294002 and H-89, were purchased from BioMol
(BIOMOL Int., Plymouth Meeting, PA).
2.2. Antibodies and Western blots
Monoclonal antibody speciﬁc to Grb2 was purchased from BD
Transduction Laboratories™ (BD Biosciences, San Jose, CA). Anti-
bodies speciﬁc to phospho-Akt (Ser473), Akt, phosphorylated forms
of Erk1/2 (Thr202/Tyr204), total Erk1/2, phospho-c-Raf (Ser259),
total IFG-IR and Gab-1 were purchased from Cell Signaling Inc.
(Danvers, MA). Polyclonal antibody speciﬁc to total c-Raf protein was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cells were collected by scraping the plates in the presence of PBS,
followed by centrifugation and lysis of the cell pellet in the
appropriate volume of RIPA buffer (50 mM Tris pH 7.4, 1% NP-40,
0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1 mM PMSF, 1 mM sodium orthovanadate, phosphatase inhibitors
and protease inhibitor cocktails). Fifteen to ﬁfty micrograms of whole
cell lysates was separated on 4–15% SDS-PAGE (BioRad, Hercules, CA).
Sample proteins separated by SDS-PAGE were transferred onto
nitrocellulose membranes (BioRad) using BioRad semi-dry blotting
system (BioRad, Hercules, CA).
2.3. Immunohistochemistry
Five samples of formalin-ﬁxed, parafﬁn-embedded HIV-Encepha-
lopathy samples were collected from the NIH funded, HIV National
tissue consortium at the Manhattan Brain Bank, Mount Sinai School of
Medicine. All samples were from the cortex and sub-cortical white
matter of the frontal lobe, and histopathologically all contain microglial
nodules and perivascular cuffs of inﬂammatory cells, including giant
multinucleated cells, pathognomonic of HIV-Encephalitis. According tothe clinical data provided by theHIVBrain Bank, allﬁve patients showed
signs of dementia, ranging from mild to moderate.
For immunohistochemistry, four micron thick sections were cut
using a microtome and placed on charged glass slides. Immunohis-
tochemistry was performed using the avidin–biotin peroxidase
methodology, according to the manufacturer's instructions (Vector
Laboratories, Burlingame, CA). Our protocol includes deparafﬁnation,
rehydration in alcohol up to water, antigen retrieval in citrate buffer
pH 6.0 at 98 °C, endogenous peroxidase quenching and blocking in
normal horse serum for 2 h at room temperature. Primary antibodies
used included a mouse monoclonal anti-Grb2 (Santa Cruz; 1:100
dilution) and a mouse monoclonal anti-Tat (ImmunoDiagnostics, Inc.,
Woburn, MA; 1:500 dilution). After rinsing with PBS, secondary
biotinylated antibodies were incubated for 1 h (1:200 dilution),
followed by avidin–biotin peroxidase complex incubation (ABC Elite
kit, Vector Laboratories, Burlingame, CA) and developed with diamino-
benzidine (DAB, Boehringer Ingelheim, Ingelheim, Germany), counter-
stained with hematoxylin and coverslipped.
For double labeling, the ﬁrst steps of the protocol are similar to the
protocol described above. However, after incubation with the ﬁrst
primary antibody, a secondary ﬂuorescein tagged antibody was
incubated for 1 h at room temperature, and after rinsing thoroughly,
the second primary antibody was incubated overnight. Finally a
second secondary antibody tagged with rhodamine was incubated for
1 h. Sections were coverslipped with aqueous based mounting media
containing DAPI and visualized under a ﬂuorescent microscope
(Olympus BX61 equipped with a DP72 camera, Center Valley, PA).
Deconvolution of selected pictures was performed using the decon-
volution software Slide Book 5 (Intelligent Imaging Innovations,
Denver, CO).
2.4. Plasmids and GST-fusion protein construction
GST-fusion Grb2 full length and the various truncated constructs
(ΔN–SH3, ΔC–SH3 and ΔNC–SH3) were generated by PCR using as
template the sequence of human Grb2 contained into the pGex-2T–
Grb2plasmid (a kindgift of Dr. Robert J. Sheaff). The primerswere: Grb2
Forward 5′-ACGGATCCATGGAAGCCATCGCCAAATATGAC, Grb2 Reverse
654 Stop 5′-ACCTCGAGTTAGACGTTCCGGTTCACGGGGG, Grb2 Δ1–69
Forward 5′-ACGGATCCATGGAAGAAATGCTTAGCAAACAGCGG, and
Grb2 Δ128–198 Reverse-stop 5′-ACCTCGAGCCGCAGGAATATCTGCT-
GGTTTCTGAGACAGATGT. Those primers were used in various combi-
nations to obtain the desired ampliﬁed sequences that were
subsequently cloned into pGex-5x1 expression vector (GE Healthcare
Bio-Sciences Corp., Piscataway, NJ) between BamHI and XhoI sites
(labeled in bold). Wild type and deletion mutants of Grb2 were also
subcloned into pmCherry vector (BD Biosciences Clontech, Mountain
View, CA) between NotI and EcoRI sites.
The GST–Tat (truncated Tat86, Tat72, Tat50) constructs have
been previously described [29]. To generate GST–Tat101 wild type fusion
protein the PCR primers were: Forward 5′-ACAAGGTACCATGGAGCCAG-
TAGATCCTAGC, and Reverse 5′-ACGCGGCCGCTCAAGCGCTCGGATCT-
GTCTCTG.
To generate pEYFP-Tat101 fusion protein, the PCR primers were:
Forward 5′-ACAAGGTACCATGGAGCCAGTAGATCCTAGC, and Reverse
5′-ACGGATCCTCAAGCGCTCGGATCTGTCTCTG. The PCR product was
cloned into pEYFP-C1 plasmid (BD Biosciences Clontech, Mountain
View, CA) between KpnI and BamHI sites.
2.5. GST-pull-down assays
Expression and puriﬁcation of GST fusion proteins were performed
according to the manufacturer's instructions. 300–400 μg of protein
lysates from LN229 cells was incubated with puriﬁed GST–Tat fusion
proteins (1 μg) bound to glutathione-agarose beads or from Tat-
expressing LN229 cell lysates that were incubated with GST–Grb2
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rotator. The glutathione-agarose resin was centrifuged at 14,000 ×g
for 3 min and washed 3 times with ice-cold RIPA buffer. Precipitated
proteins were suspended in 2× SDS protein-loading buffer, boiled for
5 min, and subjected to 4–15% SDS-PAGE; this was followed by
electrotransfer and immunoblot analysis as described above.2.6. SH3 domain prediction
Prediction of SH3 domain interacting sites was performed using
SH3-Hunter (http://cbm.bio.uniroma2.it/SH3-Hunter/) [30].2.7. Protein kinase A (PKA) kinase assay
PKA activity was measured using commercially available kit (PKA
assay kit, Upstate, Lake Placid, NY), according to the manufacturer's
instructions. In brief, LN229 cells were transfected, serum starved for
24 h and IGF-1 stimulated, as described above. Prior to lysis cells were
washed twice with ice-cold PBS, scraped and lysed with RIPA buffer.
For measurement of PKA activity in cellular extracts, 60 μg protein
lysates were incubated with kemptide, ATP, cAMP and 2 μCi of [γ-32P]
ATP in the presence of PKC/CaMK inhibitor cocktail for 10 min at
30 °C. Samples from each reaction were spotted on P81 phospho-
cellulose membrane, and the reaction was stopped by immersion of
the membrane discs in 0.75% phosphoric acid. Amount of incorporat-
ed [γ-32P] into the substrate was counted using a multipurpose
scintillation counter (Beckman LS6500).2.8. HIV-1 LTR transactivation assay
LN229 cells were co-transfected with pEYFP-Tat101, pmCherry-
Grb2 wild type or truncated mutants, an pHIV LTR–Fireﬂy luciferase
reporter plasmid [31] and a Renilla luciferase control pRL–TK plasmid
(Promega, Madison, WI) using Fugene 6 (Roche Diagnostics Corp.,
Indianapolis, IN). Cells were collected 24 h after transfection and
subjected to luciferase assay, as per the manufacturer's recommen-
dations (Promega, Madison, WI). Fireﬂy values were normalized with
Renilla as a mean of transfection efﬁciency.2.9. Statistics
Results were analyzed by an unpaired, two- or one-sided Student's
t-test. p-values≤0.05 were considered statistically signiﬁcant.Fig. 1. Tat protein contains two putative SH3 domain-binding sites. A) Amino acid sequence o
proteins predicted to bind TAT using SH3 Hunter web server (http://cbm.bio.uniroma2.it/SH
in the Tat protein. The second column gives names of domains of interacting proteins. The
reliability (sensitivity and precision) of the prediction.3. Results
3.1. Tat protein contains two putative SH3 domain-binding sites
Bioinformatic analysis using SH3Hunterweb server (http://cbm.bio.
uniroma2.it/SH3-Hunter/) [30] revealed the presence of two putative
SH3 binding domains in the amino acid sequence of HIV-Tat full length.
Given an input query protein sequence, the server identiﬁes peptides
containing poly-proline binding motifs (PxxP) and associates them to a
list of SH3 domains, in order to create peptide–domain pairs. As shown
in Fig. 1A Tat protein sequence contains two putative SH3 domain
binding sites residing in the N-terminal and C-terminal parts of the
protein between amino acids 3–8 and 81–86, respectively. According to
the SH3 Hunter program Tat is predicted to interact with RNA-binding
protein Fus1 with a signiﬁcantly high score of 0.976 and reliability
(sensitivity and precision) of 95% and 60%, respectively (Fig. 1B).With a
slightly lower score of 0.967, the C-terminus of Tat could interact with
growth factor receptor-bound protein 2 domain C (Grb2-C), Grb2
homolog in Caenorhabditis elegans (Sem5), Endophilin-A1 (End2) and
Endophilin-A3 (End3) proteins with sensitivity of 57% and with
precision of 70%. Further, Tat is also predicted to interact with much
lower scores but with higher sensitivitywith Grb2-C, signal transducing
adaptor molecule SH3 domain and ITAM motif 1 (STAM-1), and End2.
Most of the proteins were predicted to bind poly-proline motif located
between 81 and 86 amino acids of Tat protein. However, two domains,
End2 and Grb2-C, showed ability to bind the proline rich motif of Tat
located in the N-terminus.
3.2. Tat directly interacts with Grb2 protein
Since the SH3 domains of Grb2were recurrent in the list we decided
to test Tat–Grb2 interaction in vitro by GST-pull-down assay. The full-
length Tat101 and three deletion mutants were cloned into the pGex
plasmids (Fig. 2A). Tat101 and Tat1–86 constructs comprised both SH3
putative binding sites; Tat1–50 contained the N-terminal putative SH3
binding site, whereas Tat50–72was depleted of both. Fig. 2B shows that
Tat101 (full length) as well as Tat1–86 deletionmutant was able to pull
down Grb2 protein from LN229 whole cell lysate. Some degree of
binding was detected with GST–Tat1–50, while the Tat50–72 mutant,
lacking both PxxP motifs, failed to pull down Grb2. Next, we generated
Tat mutants (pEYFP-Tat101) in which the proline residues within the
SH3 binding domains were substituted with alanines as follows: single
SH3 mutants had prolines 3 and 6 (P3/6A) and 81 and 84 (P81/84A)
changed, respectively; the double mutant contained all four proline
residues mutated to alanines (P3/6/81/84A). LN229 cells were trans-
fectedwith thesemutants andwith the control Tatwild-type. Results of
GST-pull-down assays show that both single pEYFP-Tat–SH3 mutantsf Tat showing two possible SH3 binding sites (in bold). B) List of SH3 domain containing
3-Hunter/). The ﬁrst column represents amino acid sequence of peptide and its location
last three columns in the output deﬁne respectively the signiﬁcance (score) and the
Fig. 2. Tat directly interacts with Grb2. A) Scheme of GST–Tat full-length and various mutants cloned into pGex-5x-1 plasmid for GST-fusion protein expression. B) Western blot to
detect Grb2 pulled down using wild type Tat101 or the various mutants. C+ represents whole cell lysate (15 μg). C) GST–Grb2 pull-down of Tat from cells transfected with Tat
bearing a single SH3-binding domain mutated (P3/6A and P81/84A, respectively), the double mutation (P3/6/81/84A) or the wild type Tat (WT). D) Scheme of GST–Grb2 mutants.
Grb2 full-length and three mutants ΔN, ΔC, and ΔN/C were cloned into pGex-5x-1 plasmid for GST-fusion protein expression. E) Western blot to detect Grb2 interaction with Tat in
cells transfected with Tat101. F) Immunoblot shows that Grb2 wt and Grb2–SH3-C can efﬁciently pull down Gab1, while recombinant Tat competes with Gab1 for the binding to
Grb2 (Panel G).
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although less efﬁciently thanwild-type Tat (lane 5). The double mutant
of Tat, inwhich a total of four proline residueswere changed to alanines
(P3/6/81/84A), was not pulled down by Grb2 (Fig. 2C, lane 4),
conﬁrming the prediction analysis that both putative SH3 binding
domains of Tat may bind Grb2.
Grb2protein carries two SH3domains, SH3-1 (N-terminal) and SH3-
2 (C-terminal), separated by one Src homology 2 (SH2) domain
positioned in the middle of the protein. We cloned three GST-tagged
truncated fragments of Grb2 consisting of either SH3-1 (ΔC) or SH3-2
(ΔN), or depleted of both SH3 domains (ΔN/C) aswell as the full length
(WT) (Fig. 2D). The four Grb2 expressing constructs were examined for
their ability to pull down Tat from Tat-expressing cells (Fig. 2E). Results
conﬁrmed that Grb2 full length directly interactedwith Tat, and, among
the mutants, the C-terminal SH3 domain of Grb2 (ΔN) pulled down Tat
more efﬁciently than theN-terminal domain (ΔC) or themutant lacking
both SH3 domains (ΔN/C).
The Grb2-associated binder 1 (Gab1) protein has been reported to
bind with high afﬁnity to the C-terminal SH3 domain of Grb2 [32]. The
speciﬁcity of such Grb2/Gab1 interaction was conﬁrmed in our system
by GST pull-down experiments showing that Gab1 can be efﬁciently
pulleddownbyGrb2–SH3-Cbut notGrb2–SH3-NorGrb2–SH2(Fig. 2F).
We then performed a competition assay in which Gab1 was pulled
down by GST–Grb2–SH3-C in the absence or presence of recombinant
Tat (Fig. 2G).Asexpected, Grb2–SH3-CpulleddownGab1 in the absence
of Tat; however, addition of 1 μg of recombinant Tat efﬁciently
competed with Gab1 for binding to the C-terminal domain of Grb2.
Taken together these results suggest that the interaction between
Tat and Grb2 is mediated by the PxxP motifs of Tat and the C-terminal
SH3 domain of Grb2.
The Tat–Grb2 interactionwas additionally evaluated in cases of HIV-
Encephalitis. Fig. 3 shows representative images of HIVE brain tissue
samples immunolabeled with Grb2 (Fig. 3A) and Tat (Fig. 3B and C). Of
note, Tat-positive cells, mainly reactive astrocytes, are present only in
areas of inﬂammation (Panel B), while areas within the same brain
sample which do not show signs of inﬂammation are also negative for
Tat expressing cells (Panel C). Immunoﬂuorescence performed on aconsecutive section demonstrates colocalization between Tat and Grb2
in the cytoplasm of reactive astrocytes (Fig. 3E, D, and F); while
immunohistochemistry for p24 (Panel G) shows areas of viral
replication. Immunoﬂuorescence analysis further conﬁrmed that p24-
positive cells are also positive for Tat (Fig. 3H–J).
Immunoﬂuorescence analysis of Tat/Grb2 interaction was addi-
tionally performed on LN229 cell cultures. Panels A through F of Fig. 4
show representative images of Grb2 immunolabeling (in red) in cells
transfected with the control pEYFP or YFP-Tat plasmids (in green),
respectively. The colocalization of Tat with Grb2 is enhanced in these
cells due to the subcellular distribution of Tat, which takes Grb2 to the
nuclear compartment.
3.3. Impairment of ERK1/2 activation by Tat
Next, we asked whether the direct binding of Tat with Grb2 was
functional. To this end we have utilized the LN229 Glioblastoma cell
line and the IGF-1R signaling system. We ﬁrst examined the phos-
phorylation status of ERK1/2 in Tat-expressing Glioblastoma cells
upon IGF-1 stimulation. LN229 cells were transfected with pEYFP-Tat
or pEYFP, as a control, serum-starved for 24 h and then stimulatedwith
IGF-1 for 2 and 10 min (Fig. 5). Results fromWestern blot analysis show
basal levels of phospho-ERKs at time 0. IGF-1 stimulation in pEYFP-
transfected cells resulted in increased activation of ERKs after 2 or
10 min of stimulation; whereas less phosphorylation of ERK1/2 was
observed in Tat-transfected cells at the same time points. Reduced
phosphorylation of ERKs might be due, at least in part, to the Tat-
mediated nuclear translocation of Grb2, as we observed by immuno-
ﬂuorescence (Fig. 4). No differencewas observed in respect to phospho-
Akt levels (data not shown). Expression of Tat in LN229 did not affect
levels of expression of IGF-IR (Fig. 5, lower panel).
3.4. Tat-mediated increased phosphorylation of c-Raf S259 inhibitory
site involves the binding of Tat with Grb2
To get inside the functional implication of Grb2–Tat interaction,
we analyzed molecules in the Raf–MEK–MAPK pathway. No changes
Fig. 3. Detection of Grb2 and HIV-1 Tat in HIV-Encephalitis. Immunohistochemistry analysis shows the presence of Grb2 in the cytoplasm of reactive astrocytes in areas of neuro-
inﬂammation (Panel A). The HIV-1 transactivator protein Tat is detected in endothelial cells, perivascular macrophages and robustly in the cytoplasm of reactive astrocytes in areas
of encephalitis (Panel B). In contrast, non-affected areas of the brain within the same section show no expression of Tat (Panel C). Double labeling corroborates the modest presence
of Grb2 (Panel D, rhodamine), and abundant expression of Tat (Panel E, ﬂuorescein), in the cytoplasm of astrocytes, where the two proteins co-localize (Panel F), as demonstrated by
deconvolution imaging (insets). G) Immunohistochemistry analysis to detect p24 in HIVE. H, I, J) Immunolabeling shows the presence of Tat in reactive astrocytes also positive for
p24. Original magniﬁcation for all panels is 600× and 1000× in the insets.
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studied the phosphorylation status of c-Raf on the activation sites
Y340/Y341 (data not shown). We then determined the levels of c-Raf
phosphorylation on Serine 259 (S259) inhibitory site in LN229 cells
transfected with pEYFP, pEYFP-Tat, pEYFP-Tat and pmCherry–Grb2 or
pmCherry–Grb2 only. Cells, transfected and controls, were serum-
starved for 24 h prior to stimulation with IGF-1 for 2 and 10 min
(Fig. 6A). No phosphorylation was observed in control (pEYFP-Fig. 4. Co-localization of Grb2 and Tat in LN229 cells. Representative images show Tat and G
Note the diffuse cytoplasmic immunolabeling of Grb2 in control pEYFP transfected cells (Pan
magniﬁcation is 100×.transfected cells) at time zero, and addition of IGF-1 resulted in higher
levels of phosphorylated c-Raf, conﬁrming previous studies [33]. Tat
expressing cells showed high level of phosphorylation of c-Raf (S259)
without IGF-1 stimulation and treatment with IGF-1 did not further
increase phospho-c-Raf levels (Fig. 6A, lanes 4–6). If Tat/Grb2
interaction is involved in increased levels of phospho-c-Raf, over-
expression of Grb2 might restore IGF-1-dependent phosphorylation
of c-Raf on S259. PmCherry–Grb2 vector was transfected alone orrb2 co-localization in LN229 cells transfected with pEYFP and pEYFP-Tat, respectively.
els B and C), and its nuclear translocation when Tat is present (Panels E and F). Original
Fig. 5. Inhibitory effect of Tat in IGF-IR-mediated ERK1/2 phosphorylation. Represen-
tative Western blot showing activation of MAP kinases Erk1/2 by IGF-1 (40 ng/ml) in
pEYFP or pEYFP-Tat expressing cells at the time points of 0, 2 and 10 min (upper panel).
Total ERKs indicate equal loading (middle panel). Expression of IGF-IR is not affected
by Tat (lower panel).
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expression of Grb2 was able to reduce phosphorylation of c-Raf
(S259) in Tat-expressing cells. In general, overexpression of Grb2
alone resulted in a slightly higher level of phospho-c-Raf S259 at time
0, but, upon induction with IGF-1, the cells behaved essentially as the
controls (Fig. 6A, lanes 10–12). Next, we determinedwhich SH3 site of
Grb2 is more important in preventing the Tat-mediated increase of
phospho-c-Raf S259. LN229 cells were transfected with Tat together
with Grb2 full-length and the three mutants, ΔN, ΔC, and ΔN/C.
Serum-starvation and stimulation were done as described in Panel A.
Expression of Grb2 WT inhibited phosphorylation of c-Raf S259 upon
IGF-1 stimulation (Fig. 6B, lanes 1–3). Expression of Grb2–ΔC or
Grb2–ΔN/C had little effect on phosphorylation of c-Raf (Fig. 6B, lanes
7–12). Conversely, the C-terminal SH3 domain of Grb2 was able to
inhibit phosphorylation of S259 inhibitory site of c-Raf in LN229 Tat-
transfected cells even better than full-length Grb2 protein (Fig. 6B,
lanes 4–6). As a result of inhibition of phosphorylation of c-Raf S259
caused by WT or ΔN Grb2 expression, ERK activation was restored in
those samples (data not shown).
3.5. Protein kinase A (PKA) phosphorylates c-Raf (S259)
Previous studies have shown that c-Raf could be phosphorylated
on its inhibitory site S259 by two kinases protein kinase A (PKA) or
AKT/protein kinase B (PKB) [34–36]. To investigate which of these
two kinases was involved in the phosphorylation of c-Raf (S259) inFig. 6. Phosphorylation of S259 inhibitory site of c-Raf is increased in Tat-transfected
Glioblastoma LN229 cells. A) Western blot analysis to detect phosphorylation levels of
c-Raf S259. Fold ratio of time 0 (lane 1) accepted as 1. B) Phosphorylation levels of c-Raf
S259 and Erk1/2 in Tat overexpressing LN229 cells transfected together with Grb2 full-
length and three mutants ΔN, ΔC, and ΔN/C were detected by Western blot. Total c-Raf
indicates equal loading. Experiments were repeated at least 3 times; representative
Western blot is shown in the ﬁgure.our system we used speciﬁc compounds to inhibit PKA or PI3-K.
LN229 cells were transfected with pEYFP (lanes 1–4) or pEYFP-Tat
(lanes 5–8), serum-starved for 24 h, pretreated with speciﬁc in-
hibitors (50 μM of LY294002, and 25 μM of H89, lanes 3 and 7, and
lanes 4 and 8, respectively) for 30 min and stimulated with IGF-1 for
the indicated times (Fig. 7A). Results illustrate inhibition of c-Raf S259
phosphorylation only in control cells treated with H89, a speciﬁc
inhibitor of PKA. PI3-K speciﬁc inhibitor LY294002 did not have any
noticeable consequence on S259 phosphorylation. Of interest, in cells
expressing Tat, both compounds had an inhibitory effect on Raf
phosphorylation.
Next, we determined whether expression of Tat alone or along
with Grb2 could affect PKA activity. LN229 cells were transfected with
pEYFP, pEYFP-Tat, Grb2/pEYFP-Tat and Grb2 alone, serum-starved for
24 h, and stimulated with IGF-1 for 0 and 10 min. Activity of PKA in
protein extracts from pEYFP-transfected cells showed slight increase
after IGF-1 stimulation (Fig. 7B, lanes 1 and 2). Tat-expressing cells
displayed a basal level of PKA activity that was about 5-fold higher
than in pEYFP-transfected cells (compare lanes 1 and 3, p≤0.05), and
addition of IGF-1 slightly decreased PKA activity (lane 4). Over-
expression of Grb2 in Tat-expressing cells was able to reduce PKA
activity (lanes 5 and 6). When Grb2 was overexpressed alone there
was no statistically signiﬁcant difference in PKA activity between
IGF-1 stimulated and non-stimulated cells (lanes 7 and 8).
3.6. Inhibitory action of Grb2 on Tat transactivation and HIV replication
The activity of Tat on the HIV-1 LTRwas evaluated in LN229 cells co-
transfectedwith a reporter plasmid containing the viral LTR and various
Grb2 constructs (Fig. 8A). Luciferase activity was determined 24 h postFig. 7. Tat-induced PKA activation mediates c-Raf (S259) phosphorylation. A) Western
blot to detect c-Raf S259 phosphorylation and activation of Erk1/2 in LN229 cells
transfected with pEYFP or pEYFP-Tat, pretreated with speciﬁc inhibitors (LY294002
50 μM, H89 25 μM) for 30 min and stimulated with IGF-1 for the indicated times. B) The
kinase activity of PKA was tested in LN229 cells transfected with pEYFP, pEYFP-Tat,
pEYFP-Tat together with Grb2 or Grb2 alone and stimulated with IGF-1 for 0 and
10 min. Activity was assayed using commercially available kit. Asterisks indicate values
statistically signiﬁcant (pb0.05). Ns: not statistically signiﬁcant.
Fig. 8. Suppression of LTR activity and inhibition of HIV-1 replication by overexpression
of Grb2 protein. A) Promoter functional assay showing activation of HIV-LTR by Tat.
LN229 cells were co-transfected with pEYFP-Tat, Grb2 wild type or truncated mutants,
an HIV LTR–Fireﬂy luciferase reporter plasmid and a Renilla luciferase control pRL-null
plasmid. 24 h later luciferase activity was measured according to the manufacturer's
protocol. Inhibition of Tat-induced LTR by Grb2 and the indicatedmutants is statistically
signiﬁcant: *p=0.00016, **p=0.00005, #p=0.000316, ##p=0.00907. B) ELISA assay
to detect p24 in the supernatant obtained from HIV-infected primary human fetal
microglia collected at day 1 (D1) andday 3 (D3) post-infectionwithHIV. In theHIV/Grb2
sample cells were transfected with Grb2 full-length 1 day prior infection with HIV-1
JF-RL. Bar graph shows the average results from three independent experiments.
Asterisk indicates pb0.001.
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activates the HIV-1 LTR, as expected. In the presence of Grb2 wild type
or themutant containing the C-terminus SH3 domain the activity of Tat
was inhibited about three-fold (70%). The mutant of Grb2 containing
the N-terminus SH3was less efﬁcient in lowering the activity of Tat and
luciferase values were reduced about 37%. Even less efﬁcient was the
Grb2 mutant lacking both SH3 domains (SH2, 25%).
Finally, we investigated the role of Grb2/Tat interaction on viral
replication. To this end we transfected human primary fetal microglia
cells with Grb2 1 day prior to their infection with HIV-1. Levels of
p24 were measured in the supernatant of cultured cells on days 1 and
3 post-infection. Fig. 8B shows an approximate 30% decrease in p24
in the medium of Grb2-transfected cells compared to control at both
days 1 and 3.
4. Discussion
The human immunodeﬁciency virus-1 transactivating factor Tat
has been shown to affect cellular functions by interfering with signal
transduction pathways [11,20,23]. This ability of Tat to interact with
many proteins may be due, at least in part, to the presence of speciﬁc
motifs in its amino acid sequence. Using SH3 Hunter bioinformatic
server [30] we have identiﬁed two putative SH3 binding domains
in the Tat protein sequence and a list of possible interacting SH3
domains (Fig. 1) such as those contained in Fus1, Sem5, Grb2-C,STAM-1, End3 andEnd2proteins. Interestingly, four of themwereeither
Grb2 (Grb2-C), Grb2 C. elegans homolog (Sem5), or Grb2-like proteins
(End3 and End2), suggesting some degree of speciﬁcity in the SH3
recognition sites present in Tat. Sem5 protein is the GRB2 homolog in
C. elegans [37,38]. End2 and End3 (full names Endophilin-A2 and
Endophilin-A3, respectively) are SH3 domain-containing GRB2-like
proteins implicated in endocytosis [39,40]. STAM-1 is a member of the
STAM (SH3 domain containing signal-transducing adaptor molecule)
family of proteins, which are composed of several domain structures,
including the VHS (Vps27/Hrs/STAM) domain, ubiquitin-interacting
motif (UIM), Src homology 3 domain, and a coiled-coil (CC) region.
Through their CC regions, both STAM-1 and STAM-2 bind Hrs
(hepatocyte growth factor-regulated substrate), a protein that is
localized on the cytoplasmic face of the early endosome [41]. Although
we investigated thoroughly only the interaction of Tat with Grb2, it is
tempting to speculate that the interaction of Tat with the above
mentioned molecules, and possibly other SH3-bearing proteins, may
result in deregulation of a wide variety of cellular processes.
Grb2 is a ubiquitously expressed adaptor protein that has mitogenic
properties and is required for several basic cellular processes [6]. It can
interact with tyrosine phosphorylated substrates, such as tyrosine
kinase receptors, via the SH2 domain and with a variety of other
signaling molecules via the two SH3 domains. Grb2 is constitutively
bound to Son of sevenless (Sos), a guanine-nucleotide exchange factor
that promotes GDP–GTP exchange on Ras, whose activation then leads
to the activation ofMAPKpathway [42,43]. Direct interaction of Tatwith
Grb2 may displace the host protein from its usual binding partners and
alter theRas/MAPKpathways. Indeed, our in vitrodata showthat Tat can
compete with Gab1 for binding to the SH3 domain of Grb2, possibly
altering Gab1 downstream cascade. An additional mechanism bywhich
Tat may deregulate Grb2 downstream signaling could be mediated, at
least in cell culture, by the subtraction of Grb2 from the cytoplasmic
events. This hypothesis is supported by our data showing nuclear
localization of Grb2 in Tat-expressing cells (Fig. 4).
Immunohistochemistry analysis of HIVE brain samples revealed a
modest presence of Grb2, mainly detected in astrocytes (Fig. 3, Panels
A through F). The pattern of HIV-Tat expression appears very robust in
area of encephalitis, where the viral protein is also detected in
endothelial cells, perivascular macrophages and reactive astrocytes. In
contrast, Tat is undetectable in areas of the same brain that are not
affected by inﬂammation. Colocalization between Tat and Grb2 was
observed in reactive astrocytes, corroborating the in vitro binding
assays. Of interest to note that, although Grb2 is abundantly expressed
in all cell types, immunohistochemistry analysis revealed strong
labeling only in reactive astrocytes. It may indicate the activation/
proliferation status of these cells, as previously suggested by C. Russo
et al. in their study demonstrating increased Grb2/ShcA/APP interac-
tion in reactive astrocytes of Alzheimer's disease (AD) brain samples
[44].
Many studies have reported the pleiotropic activity of Tat in
deregulating a wide range of signaling pathways by both direct and
indirect mechanisms. The presence of SH3-binding domains in the
sequence of Tat may account for at least some of the various activi-
ties of this viral protein. De la Fuente et al. made an interesting
observation on the ability of Tat to downregulate expression of many
cellular genes, particularly on cellular tyrosine kinase receptors (RTK)
and their downstream signal transduction members, including the
Ras–Raf–MEK pathway [45]. Perhaps impairment of the Ras/MEK
pathway by Tat/Grb2 interaction may affect transcription of ERK1/2
downstream targets. As the cellular signaling pathways are not linear
but cross-talk and overlap, Tat likely affects them at various levels in a
complex network of direct and indirect mechanisms. We have tried to
analyze some of them using a Glioblastoma cell line and the well-
known IGF-1R signaling. Following the Ras/Raf/MAPK pathway we
showed that Tat can interact at different levels; it binds to Grb2,
subtracting this adaptor molecule to the Ras/MEK pathway, while it
1843S. Rom et al. / Biochimica et Biophysica Acta 1813 (2011) 1836–1844potentiates the Raf inhibitory pathway by activating PKA. Shifting of
the substrates along signaling pathways appears to be an interesting
feature of Tat. For instance, we have previously shown the ability of
Tat to promote the non-canonical activation of Stat5A in PC12 cells
stimulated with NGF, which results in the inhibition of cellular
differentiation [46]. Ultimately, since the activity of Tat on cellular
processes appears to be cell-type speciﬁc, the end point of Tat/host
interaction, including the Tat/SH3–client interaction, could be either
inhibitory or stimulatory. For example, Tat has been shown tomediate
activation of ERK1/2 in endothelial cells [25] or to inhibit their
activation in neural cells [47]. On the other hand, the outcome of Tat/
host interaction may also affect some aspects of the viral cycle. We
utilized primary human fetal microglia infected with HIV-1 and found
that over-expression of Grb2 derails the activity of Tat from its natural
target, the viral LTR (Fig. 8A), resulting in a lower production of p24 as
a measurement of viral replication (Fig. 8B).
In summary, this report provides evidence for Tat/Grb2 direct
interaction, which is mediated by the SH3 C-terminal domain of Grb2
and polyproline regions of Tat. This interaction is functional and
bidirectional: it affects cellular pathways as well as viral replication.
Considering the high number of cellular proteins that possess one
or more SH3-binding domains, it is tempting to speculate that the Tat/
SH3 interaction might be a general mechanism for Tat to interfere
with many signaling pathways, and consequently, many cellular
processes.
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